New drug LY3971297 tested for obesity and hypertension safety
NCT ID NCT06148272
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This early-stage study tests a new drug called LY3971297 in healthy volunteers, people with obesity and high blood pressure, and those with reduced kidney function. The main goal is to check for side effects and measure how the drug moves through the body. The study involves up to 225 participants and lasts up to 90 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CenExel ACT
COMPLETEDAnaheim, California, 92801, United States
-
Clinical Pharmacology of Miami
RECRUITINGMiami, Florida, 33172, United States
Contact Phone: •••-•••-••••
Contact
-
Clinical Research Hospital Tokyo
ACTIVE_NOT_RECRUITINGShinjuku-ku, 160-0004, Japan
-
Hakata Clinic
ACTIVE_NOT_RECRUITINGFukuoka, 812-0025, Japan
-
ICON Early Phase Services
COMPLETEDSan Antonio, Texas, 78209, United States
-
Lilly Centre for Clinical Pharmacology
COMPLETEDSingapore, 138623, Singapore
-
P-One Clinic
ACTIVE_NOT_RECRUITINGHachiōji, 192-0071, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3971297
What this could lead to
If successful, this could lead to a new treatment option for obesity and high blood pressure.
What could go wrong
This is a very early Phase 1 trial focused on safety and dosing, not effectiveness. It is small and may not lead to a working treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.